Department of Radiology, College of Medicine, and Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul, Korea.
Department of Radiology, University of Ulsan College of Medicine and Asian Medical Center, Seoul, Korea.
Diagn Interv Radiol. 2020 Jan;26(1):45-52. doi: 10.5152/dir.2019.18552.
PURPOSE Most patients with intrahepatic cholangiocarcinoma (ICC) are not eligible for surgical resection due to advanced stage. We aimed to evaluate the feasibility, local tumor control, and long-term survival of intraoperative radiofrequency ablation (IORFA) with surgical resection to treat unresectable intrahepatic cholangiocarcinoma (ICC). METHODS From 2009 to 2016, 20 consecutive patients (12 primary ICC, 8 recurrent ICC) underwent curative IORFA with hepatic resection for surgically unresectable ICC. Patients were not qualified to undergo surgical resection due to multiple lesions causing postoperative hepatic insufficiency and undesirable tumor locations for surgical resection or percutaneous RFA. Of the 51 treated tumors (mean, 2.6±0.9 tumors/patient), 24 were treated by IORFA and 27 were surgically removed. The technical success and effectiveness, overall survival, progression-free survival (PFS), and complications were assessed retrospectively. The overall survival and PFS rates were estimated by the Kaplan-Meier method. RESULTS The technical success and effectiveness of IORFA were 100%. The overall survival rates at 6 months, 1, 3, and 5 years were 95%, 79%, 27%, and 14%, respectively. The median overall survival time was 22.0±3.45 months. The PFS rates at 6 months, 1, 3, and 5 years were 70%, 33%, 13%, and 13%, respectively. The median PFS was 9.0±1.68 months. The prognosis was significantly worse for patients with recurrent ICC than for patients with primary ICC. One patient (5%) had major complications due to IORFA such as liver abscess and biliary stricture. CONCLUSION IORFA with surgical resection can be a feasible option for ICC cases that are not amenable to treatment with surgical resection alone. This strategy provides acceptable local tumor control and overall survival.
由于晚期原因,大多数肝内胆管细胞癌(ICC)患者不符合手术切除条件。本研究旨在评估术中射频消融(IORFA)联合肝切除术治疗不可切除肝内胆管细胞癌(ICC)的可行性、局部肿瘤控制和长期生存。
2009 年至 2016 年,20 例连续患者(原发性 ICC12 例,复发性 ICC8 例)因手术不可切除 ICC 而行根治性 IORFA 肝切除术。由于多个病变导致术后肝衰竭和手术切除或经皮射频消融(RFA)不可取的肿瘤位置,患者不符合手术切除条件。在 51 个治疗肿瘤中(平均 2.6±0.9 个/例),24 个采用 IORFA 治疗,27 个采用手术切除。回顾性评估技术成功率和疗效、总生存率、无进展生存率(PFS)和并发症。采用 Kaplan-Meier 法估计总生存率和 PFS 率。
IORFA 的技术成功率和有效性为 100%。6 个月、1 年、3 年和 5 年的总生存率分别为 95%、79%、27%和 14%。中位总生存时间为 22.0±3.45 个月。6 个月、1 年、3 年和 5 年的 PFS 率分别为 70%、33%、13%和 13%。中位 PFS 为 9.0±1.68 个月。复发性 ICC 患者的预后明显差于原发性 ICC 患者。1 例(5%)因 IORFA 发生严重并发症,如肝脓肿和胆管狭窄。
对于不能单独手术治疗的 ICC 病例,IORFA 联合肝切除术是一种可行的选择。这种策略提供了可接受的局部肿瘤控制和总体生存率。